值得一提的是，NK-1抑制剂（如阿瑞匹坦）能精准阻断P物质与大脑NK-1受体的结合，从源头切断呕 吐信号，尤其擅长控制化疗后数天出现的延迟性呕吐。研究显示，对于高致吐性化疗，联合使用NK-1 抑制剂可将延迟性呕吐的完全控制率提升至70%以上。 对于中、高致吐风险化疗，临床常采用"黄金三角"方案：化疗前联合使用NK-1抑制剂、5-HT受体拮抗 剂和地塞米松；化疗后继续使用NK-1抑制剂和地塞米松，覆盖延迟性呕吐高发期。预防性用药至关重 要，事前干预远胜于事后补救。 除规范用药外，清淡饮食、少食多餐、避免油腻辛辣食物及注意补水等行为，也有助于减轻胃肠负担。 患者应主动向医生反馈症状，并严格遵循医嘱用药，切勿自行调整方案。另外，家属的悉心照护与心理 支持也同样重要。 通过科学的止吐方案与良好的医患配合，恶心呕吐已不再是化疗路上不可逾越的障碍。让这些副作用得 到更好的管理，将让抗癌之路走得更稳、更有质量。 陆军特色医学中心肿瘤科 罗皓 当不得不面对化疗时，许多患者因恐惧产生难以忍受的恶心呕吐而对治疗却步。实际上，现代医学已能 通过科学的止吐方案，显著减轻这些反应，让治疗之路更为平稳。 化疗引发呕吐，主要与人体大脑延髓 ...

Industry Overview - Gout is a chronic disease caused by purine metabolism disorders, characterized by hyperuricemia and the deposition of urate crystals in joints and tissues, leading to various clinical symptoms [1][2] - The gout medication market in China has grown significantly, with the market size increasing from 700 million yuan in 2015 to 2.2 billion yuan in 2024 [1][10] - The prevalence of hyperuricemia in China is approximately 14%, with a patient population of around 197 million, while gout prevalence ranges from 1% to 3%, affecting approximately 15.5 to 42.29 million people [6][8] Market Dynamics - The gout medication market is primarily driven by the increasing incidence of gout and hyperuricemia due to lifestyle changes and dietary habits [10] - The market is currently experiencing a contraction due to the entry of mainstream gout medications like febuxostat into centralized procurement, but future growth is expected as patient numbers rise [10] - By 2030, the gout medication market in China is projected to exceed 10 billion yuan [10] Product Classification - Gout medications are categorized into acute anti-inflammatory analgesics and long-term urate-lowering drugs, with urate-lowering drugs accounting for about 40% of the global market [2][4] - In the domestic market, traditional drugs like febuxostat and benzbromarone hold a market share of approximately 60% [2] Competitive Landscape - The industry is characterized by intense competition, with generic drugs dominating the market while innovative drugs are rapidly being developed [14] - Major players include Kangyuan Pharmaceutical, Huahai Pharmaceutical, Yipinhong, and Hengrui Medicine, which are focusing on developing new urate-lowering agents to address the limitations of existing medications [14][15] - The introduction of centralized procurement policies has pressured generic drug prices, prompting companies to shift towards high-value innovative drugs [14] Key Companies - Hengrui Medicine is developing a new urate-lowering drug, SHR4640, which has shown significant efficacy and low toxicity, with a market application expected in 2025 [15][18] - Yipinhong is working on AR882, a new urate excretion promoter, which has received FDA support for global clinical trials [15] - Tonghua Dongbao has expanded its product pipeline in the gout treatment area, with two new drugs in clinical trials [16] Development Trends - The industry is shifting from generic to innovative drug development, with URAT1 inhibitors becoming a research focus [20] - Biologics and long-acting therapies are emerging as new growth points, with products like SEL-212 expected to enhance patient compliance and market potential [21] - Personalized treatment and combination therapies are becoming key research directions, aiming to meet unmet clinical needs [22]